These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16502348)

  • 1. The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs.
    Rephaeli A; Entin-Meer M; Angel D; Tarasenko N; Gruss-Fischer T; Bruachman I; Phillips DR; Cutts SM; Haas-Kogan D; Nudelman A
    Invest New Drugs; 2006 Sep; 24(5):383-92. PubMed ID: 16502348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters.
    Nudelman A; Levovich I; Cutts SM; Phillips DR; Rephaeli A
    J Med Chem; 2005 Feb; 48(4):1042-54. PubMed ID: 15715472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer.
    Rephaeli A; Blank-Porat D; Tarasenko N; Entin-Meer M; Levovich I; Cutts SM; Phillips DR; Malik Z; Nudelman A
    Int J Cancer; 2005 Aug; 116(2):226-35. PubMed ID: 15800932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
    Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
    J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
    Tarasenko N; Nudelman A; Rozic G; Cutts SM; Rephaeli A
    Invest New Drugs; 2017 Aug; 35(4):412-426. PubMed ID: 28315153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
    Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
    Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex).
    Tarasenko N; Nudelman A; Tarasenko I; Entin-Meer M; Hass-Kogan D; Inbal A; Rephaeli A
    Clin Exp Metastasis; 2008; 25(7):703-16. PubMed ID: 18506586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines.
    Engel D; Nudelman A; Levovich I; Gruss-Fischer T; Entin-Meer M; Phillips DR; Cutts SM; Rephaeli A
    J Cancer Res Clin Oncol; 2006 Oct; 132(10):673-83. PubMed ID: 16826403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel anticancer prodrugs of butyric acid. 2.
    Nudelman A; Ruse M; Aviram A; Rabizadeh E; Shaklai M; Zimrah Y; Rephaeli A
    J Med Chem; 1992 Feb; 35(4):687-94. PubMed ID: 1542095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
    Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines.
    Entin-Meer M; Rephaeli A; Yang X; Nudelman A; Nudelman A; Haas-Kogan DA
    Cancer Lett; 2007 Aug; 253(2):205-14. PubMed ID: 17346876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity.
    Nudelman A; Rephaeli A
    J Med Chem; 2000 Jul; 43(15):2962-6. PubMed ID: 10956204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative antitumor properties in rodents of irreversible inhibitors of L-ornithine decarboxylase, used as such or as prodrugs.
    Claverie N; Mamont PS
    Cancer Res; 1989 Aug; 49(16):4466-71. PubMed ID: 2501026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.
    Gediya LK; Khandelwal A; Patel J; Belosay A; Sabnis G; Mehta J; Purushottamachar P; Njar VC
    J Med Chem; 2008 Jul; 51(13):3895-904. PubMed ID: 18543902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line.
    Aviram A; Zimrah Y; Shaklai M; Nudelman A; Rephaeli A
    Int J Cancer; 1994 Mar; 56(6):906-9. PubMed ID: 8119779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of pH responsive clickable prodrugs applied to histone deacetylase inhibitors: a new strategy for anticancer therapy.
    Delatouche R; Denis I; Grinda M; El Bahhaj F; Baucher E; Collette F; Héroguez V; Grégoire M; Blanquart C; Bertrand P
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):862-72. PubMed ID: 23537575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
    Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Jayle C; Alsarraf J; Thomas M; Papot S
    Eur J Med Chem; 2013 Sep; 67():75-80. PubMed ID: 23845743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical analysis of acetylation, proliferation, mitosis, and apoptosis in tumor xenografts following administration of a histone deacetylase inhibitor--a pilot study.
    Mitić T; McKay JS
    Toxicol Pathol; 2005; 33(7):792-9. PubMed ID: 16392174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
    Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.